Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • live-attenuated vaccine
Breakthrough in Enteric Fever Prevention: Efficacy and Safety of the Novel Salmonella Paratyphi A Vaccine CVD 1902
Posted inInfectious Diseases news Public Health

Breakthrough in Enteric Fever Prevention: Efficacy and Safety of the Novel Salmonella Paratyphi A Vaccine CVD 1902

Posted by MedXY By MedXY 10/31/2025
A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.
Read More
Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers
Posted inPediatrics Public Health Specialties

Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers

Posted by MedXY By MedXY 08/28/2025
This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.
Read More
  • Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant
  • Revolutionizing iTTP Treatment: Reverse CAR T Cells Target Autoreactive B Cells with Precision
  • Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring
  • Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy
  • Antifungal Therapy Slashes Mortality in COVID-19-Associated Pulmonary Aspergillosis: European Data Confirms
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in